Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. Review uri icon

Overview

abstract

  • Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.

publication date

  • January 30, 2018

Research

keywords

  • Breast Neoplasms
  • Cyclin-Dependent Kinases
  • Drug Resistance, Neoplasm
  • Protein Kinase Inhibitors
  • Receptor, ErbB-2

Identity

Scopus Document Identifier

  • 85045754758

Digital Object Identifier (DOI)

  • 10.1002/cpt.965

PubMed ID

  • 29226311

Additional Document Info

volume

  • 103

issue

  • 6